View Older Stories View More Recent Stories

Jan 16, 2018 05:02PM Exelixis (EXEL), Ipsen Report Phase 3 Trial Results of Cabozantinib Demonstrating Significant OS Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
Jan 16, 2018 05:01PM Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
Jan 9, 2018 08:00AM Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Jan 8, 2018 08:08AM Exelixis (EXEL) And StemSynergy Enter into Pact for Discovery and Development of Novel Anticancer Therapies
Jan 8, 2018 08:00AM Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies
Jan 4, 2018 08:05AM Exelixis (EXEL) Amends Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Jan 4, 2018 08:00AM Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Dec 19, 2017 02:59PM Exelixis (EXEL) Confirms FDA Approval of CABOMETYX Tablets for Previously Untreated Advanced RCC
Dec 19, 2017 02:54PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Nov 22, 2017 05:41AM Exelixis (EXEL) to Present Phase 3 CELESTIAL Trial Results of Cabozantinib at 2018 ASCO-GI Symposium
Nov 21, 2017 04:45PM Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations
Nov 21, 2017 04:30PM Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium
Nov 7, 2017 04:05PM Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14th
Nov 1, 2017 04:05PM Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 26, 2017 04:10PM Exelixis to Present at the Credit Suisse 26th Annual Healthcare Conference on November 7th
Oct 18, 2017 04:05PM Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017
Oct 16, 2017 07:00AM Exelixis (EXEL) Granted U.S. FDA Priority Review for CABOMETYX as Treatment for Previously Untreated Advanced Renal Cell Carcinom
Oct 16, 2017 06:59AM Exelixis (EXEL) Reports Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
Oct 16, 2017 06:59AM Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
Oct 16, 2017 06:58AM Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Oct 4, 2017 08:03AM Exelixis (EXEL) to Receive Milestone Payment from Bristol-Myers Squibb (BMY) for RORγt Inverse Agonist Program
Oct 4, 2017 08:00AM Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORγt Inverse Agonist Program
Sep 24, 2017 09:00PM Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study
Sep 19, 2017 04:05PM Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25
Sep 11, 2017 05:55AM Exelixis (EXEL) & Ipsen Reports Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib at ESMO 2017
Sep 9, 2017 06:12PM Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
Sep 9, 2017 06:09PM Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
Sep 7, 2017 08:16AM Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy
Sep 6, 2017 05:23PM Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress
Aug 29, 2017 04:05PM Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
Aug 16, 2017 07:04AM Exelixis (EXEL) Submits sNDA for CABOMETYX for Treatment of Previously Untreated Advanced Kidney Cancer
Aug 16, 2017 07:00AM Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer
Aug 2, 2017 04:05PM Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 1, 2017 08:00AM Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress
Jul 20, 2017 07:07AM Exelixis (EXEL), Genentech Reach Settlement in Dispute Regarding Companies' Collaboration Agreement for Cobimetinib
Jul 20, 2017 07:00AM Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib
Jul 17, 2017 04:05PM Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
Jul 10, 2017 08:06AM Bristol-Myers Squibb (BMY) & Exelis (EXEL) Commence Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo & Yervoy in Combination with CABOMETYX
Jul 10, 2017 08:00AM Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Adv
Jun 29, 2017 08:00AM Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness
Jun 19, 2017 08:01AM Exelixis (EXEL) Reports Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib Versus Sunitinib
Jun 19, 2017 08:00AM Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
Jun 12, 2017 08:22AM Exelixis (EXEL) Commences Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Jun 12, 2017 08:05AM Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Jun 8, 2017 04:05PM Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13
May 3, 2017 04:05PM Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 1, 2017 04:05PM Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update
Apr 24, 2017 04:05PM Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3
Apr 18, 2017 04:05PM Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017
Apr 4, 2017 04:05PM Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories